ROCKET-AF

Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and embolism in AF

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 14,264 patients with non-valvular AF at moderate-high stroke risk, rivaroxaban was non-inferior to warfarin for stroke or systemic embolism, with less intracranial bleeding.

14 264

Schéma

Double-blind, double-dummy RCT

Critère

Stroke or systemic embolism

Pertinence

Résultat1.7 %/yr vs 2.2 %/yr. ICH 0.5 % vs 0.7 %.

Patel MR, et al. N Engl J Med. 2011;365(10):883-891. 10.1056/NEJMoa1009638

Discussion et critique

Warfarin TTR ~ 55 % — low by modern standards; argued to inflate rivaroxaban performance. Once-daily dosing favours adherence.